Impaired complex-I mitochondrial biogenesis in parkinson disease frontal cortex

Journal of Parkinson's Disease

Volumn 2, Issue 1, 2012, Pages 67-76

  Thomas, Ravindar R ^a   Keeney, Paula M ^a   Bennett, James P ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complex I; gene expression; microRNA; mitochondrial biogenesis; Parkinson's disease

Indexed keywords

DIETHYLENETRIAMINE; MICRORNA; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; TRANSCRIPTION FACTOR NRF1; TUMOR NECROSIS FACTOR ALPHA;

ACAD9 GENE; ARTICLE; BIOGENESIS; COMPLEX I DEFICIENCY; COMPLEX I GENE; CONTROLLED STUDY; DOWN REGULATION; ELECTRON TRANSPORT; FRONTAL CORTEX; GENE EXPRESSION REGULATION; GENE INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; MITOCHONDRIAL GENE; MITOCHONDRIAL GENOME; NITROSATIVE STRESS; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ACYL-COA DEHYDROGENASES; ADOLESCENT; CELL LINE; DNA-BINDING PROTEINS; DOPAMINERGIC NEURONS; ELECTRON TRANSPORT COMPLEX I; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MITOCHONDRIAL PROTEINS; MITOCHONDRIAL TURNOVER; NEURAL STEM CELLS; NUCLEAR RESPIRATORY FACTOR 1; PARKINSON DISEASE; ROTENONE; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859345475     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2012-11074     Document Type: Article

References (37)

1. Bertrand E, Lechowicz W, Szpak GM, Lewandowska E, Dymecki J, & Wierzba-Bobrowicz T (2004) Limbic neuropathology in idiopathic Parkinson's disease with concomitant dementia. Folia Neuropathol, 42, 141-150. (Pubitemid 39433399)
2. Braak E, Sandmann-Keil D, Rub U, GaiWP, deVos RA, Steur EN, Arai K, & Braak H (2001) alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol (Berl), 101, 195-201. (Pubitemid 32219751)
3. Braak H, de Vos RA, Bohl J, & Del Tredici K (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's diseaserelated brain pathology. Neurosci Lett, 396, 67-72. (Pubitemid 43233790)
4. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211. (Pubitemid 36007810)
5. Braak H, Ghebremedhin E, Rub U, Bratzke H, & Del Tredici K (2004) Stages in the development of Parkinson's diseaserelated pathology. Cell Tissue Res, 318, 121-134. (Pubitemid 39362633)
6. Braak H, Sandmann-Keil D, GaiW, & Braak E (1999) Extensive axonal Lewy neurites in Parkinson's disease: A novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett, 265, 67-69. (Pubitemid 29210200)
7. Del Tredici K, Rub U, DeVos RA, Bohl JR,&BraakH(2002) Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol, 61, 413-426. (Pubitemid 34533671)
8. Chaudhuri KR, Odin P, Antonini A, & Martinez-Martin P (2011) Parkinson's disease: The non-motor issues. Parkinsonism Relat Disord, 17, 717-723.
9. Chaudhuri KR, & Schapira AH (2009) Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol, 8, 464-474.
10. Belin AC, & Westerlund M (2008) Parkinson's disease: A genetic perspective. FEBS J, 275, 1377-1383.
11. Lesage S,&Brice A (2009) Parkinson's disease: From monogenic forms to genetic susceptibility factors. Hum Mol Genet, 18, R48-R59.
12. Bardien S, Lesage S, Brice A, & Carr J (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Impaired Mitobiogenesis in Parkinson's Parkinson's disease. Parkinsonism Relat Disord, 17, 501-508.
13. Burbulla LF, & Kruger R (2011) Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. J Neurol Sci, 306, 1-8.
14. Sato S, & Hattori N (2011) Genetic mutations and mitochondrial toxins shed new light on the pathogenesis of Parkinson's disease. Parkinsons Dis, 2011, 979231.
15. Yue Z,&LachenmayerML(2011) GeneticLRRK2models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov Disord, 26, 1386-1397.
16. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, & Scherzer CR (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med, 2, 52ra73.
17. Scarpulla RC (2011) Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta, 1813, 1269-1278.
18. Keeney PM, Xie J, Capaldi RA, & Bennett JP Jr (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci, 26, 5256-5264. (Pubitemid 44315308)
19. Arthur CR, Morton SL, Dunham LD, Keeney PM, & Bennett JP Jr (2009) Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Mol Neurodegener, 4, 37.
20. Scarpulla RC (2006) Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem, 97, 673-683.
21. Scarpulla RC (2008) Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev, 88, 611-638. (Pubitemid 351520089)
22. Borland MK,Mohanakumar KP, Rubinstein JD, Keeney PM, Xie J, Capaldi R, Dunham LD, Trimmer PA, & Bennett JP Jr (2009) Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim Biophys Acta, 1792, 68-74.
23. Nouws J, Nijtmans L, Houten SM, Van den Brand M, Huynen M, Venselaar H, Hoefs S, Gloerich J, Kronick J, Hutchin T, Willems P, Rodenburg R, Wanders R, Van den Heuvel L, Smeitink J, & Vogel RO (2010) Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. Cell Metab, 12, 283-294.
24. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, & Dawson TM (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell, 144, 689-702.
25. Junn E, & Mouradian MM (2012) MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther, 133, 142-150.
26. Nagatsu T (2002) Parkinson's disease: Changes in apoptosisrelated factors suggesting possible gene therapy. J Neural Transm, 109, 731-745. (Pubitemid 34810770)
27. Yokoyama H, Uchida H, Kuroiwa H, Kasahara J, & Araki T (2011) Role of glial cells in neurotoxin-induced animal models of Parkinson's disease. Neurol Sci, 32, 1-7.
28. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, & Scherzer CR (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med, 2, 52ra73.
29. Acin-Perez R, Fernandez-Silva P, Peleato ML, Perez-Martos A, & Enriquez JA (2008) Respiratory active mitochondrial supercomplexes. Mol Cell, 32, 529-539.
30. Moore DJ, West AB, Dawson VL, & Dawson TM (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci, 28, 57-87.
31. Drose S, Krack S, Sokolova L, Zwicker K, Barth HD, Morgner N, Heide H, Steger M, Nubel E, Zickermann V, Kerscher S, Brutschy B, Radermacher M, & Brandt U (2011) Functional dissection of the proton pumping modules of mitochondrial complex I. PLoS Biol, 9, e1001128.
32. Hunte C, Zickermann V, & Brandt U (2010) Functional modules and structural basis of conformational coupling in mitochondrial complex I. Science, 329, 448-451.
33. Iyer S, Thomas RR, Portell FR, Dunham LD, Quigley CK, & Bennett JP Jr (2009) Recombinant mitochondrial transcription factorAwith N-terminal mitochondrial transduction domain increases respiration and mitochondrial gene expression. Mitochondrion, 9, 196-203.
34. Iyer S, Xiao E, Alsayegh K, Eroshenko N, Riggs MJ, Bennett JP Jr, & Rao RR (2011) Mitochondrial gene replacement in human pluripotent stem cell-derived neural progenitors. Gene Ther.
35. Keeney PM, Quigley CK, Dunham LD, Papageorge CM, Iyer S, Thomas RR, Schwarz KM, Trimmer PA, Khan SM, Portell FR, Bergquist KE, & Bennett JP (2009) Mitochondrial Gene Therapy Augments Mitochondrial Physiology in a Parkinson's Disease Cell Model. Hum Gene Ther, 20, 897-907.
36. Khan SM, & Bennett JP Jr (2004) Development of mitochondrial gene replacement therapy. J Bioenerg Biomembr, 36, 387-393. (Pubitemid 39619846)
37. Thomas RR, Khan SM, Portell FR, Smigrodzki RM, & Bennett JP Jr (2011) Recombinant human mitochondrial transcription factor A stimulates mitochondrial biogenesis and ATP synthesis, improves motor function after MPTP, reduces oxidative stress and increases survival after endotoxin. Mitochondrion, 11, 108-118.